Dr. Srinivas Sankarnaga Devarakonda, MD

Dr. Devarakonda practices at Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center.

Dr. Devarakonda's NPI, 1154595049, was assigned on April 22, 2008. Dr. Devarakonda graduated from Osmania Medical College NTR UHS in 2003. Dr. Devarakonda holds Ohio license 35133922.

Dr. Devarakonda's primary practice is Ohio State University Hospital, at 410 West 10th Avenue, Columbus, OH 43210 in Franklin County. The practice phone is (614) 293-9700.

Dr. Devarakonda's primary practice is Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center. Dr. Devarakonda is also affiliated with The James Cancer Hospital and Solove Research Institute. The medical group on file is Ohio State University Physicians. Dmand AI also links Dr. Devarakonda to 2 more hospital outpatient departments and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Devarakonda practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Devarakonda's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Devarakonda is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Devarakonda's licenses on file in 4 states: Ohio, Louisiana, Pennsylvania and Massachusetts.

Dmand AI lists chronic anemia, chronic leukemia, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Devarakonda treats.

CMS data shows 420 Medicare services from Dr. Devarakonda across 5 procedure codes in 2024, for 203 Medicare patients. Medicare paid $42,291 for them.

CMS counts 203 Medicare patients who saw Dr. Devarakonda in 2024. The largest group is 65 to 74, with 109 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Devarakonda's median patient age at 68, with 41% women.

In 2024, Dr. Devarakonda wrote 63 Medicare Part D claims for 26 patients. 76% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $238 in total drug cost. In 2022, CMS named 49 claims across 2 drugs.

Dr. Devarakonda accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Devarakonda as offering telehealth.

Dmand AI links 48 papers to Dr. Devarakonda, published from 2008 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Multiple Myeloma, Hematopoietic Stem Cell Transplantation and Antineoplastic Combined Chemotherapy Protocols. Dr. Devarakonda has published most often in Front Oncol. Dr. Devarakonda's most frequent co-authors are Naresh Bumma, MD, Don Michael Benson, MD and Ashley Elizabeth Rosko, MD.

Dmand AI links Dr. Devarakonda to 13 clinical trials, 5 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Multiple Myeloma, Melanoma and Blood Protein Disorders. National Cancer Institute (NCI) sponsors the most, 6. Open Payments lists research payments to Dr. Devarakonda that name 2 trials.

CMS Open Payments shows 91 general payments to Dr. Devarakonda from 25 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. Janssen Research & Development, LLC paid the most, $7,440. It also lists 38 research payments totaling $24,717 from 2016 to 2017, naming 2 clinical trials.

Dr. Devarakonda graduated from Osmania Medical College NTR UHS in 2003.

Dr. Devarakonda is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Molina. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.